OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
John B. Buse, Deborah J. Wexler, Απόστολος Τσάπας, et al.
Diabetes Care (2019) Vol. 43, Iss. 2, pp. 487-493
Open Access | Times Cited: 1050
John B. Buse, Deborah J. Wexler, Απόστολος Τσάπας, et al.
Diabetes Care (2019) Vol. 43, Iss. 2, pp. 487-493
Open Access | Times Cited: 1050
Showing 1-25 of 1050 citing articles:
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
Dawn Kleindorfer, Amytis Towfighi, Seemant Chaturvedi, et al.
Stroke (2021) Vol. 52, Iss. 7
Open Access | Times Cited: 1994
Dawn Kleindorfer, Amytis Towfighi, Seemant Chaturvedi, et al.
Stroke (2021) Vol. 52, Iss. 7
Open Access | Times Cited: 1994
GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
Michael A. Nauck, Daniel R. Quast, Jakob Wefers, et al.
Molecular Metabolism (2020) Vol. 46, pp. 101102-101102
Open Access | Times Cited: 962
Michael A. Nauck, Daniel R. Quast, Jakob Wefers, et al.
Molecular Metabolism (2020) Vol. 46, pp. 101102-101102
Open Access | Times Cited: 962
KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Ian H. de Boer, Maria Luiza Caramori, Juliana C.N. Chan, et al.
Kidney International (2020) Vol. 98, Iss. 4, pp. S1-S115
Open Access | Times Cited: 962
Ian H. de Boer, Maria Luiza Caramori, Juliana C.N. Chan, et al.
Kidney International (2020) Vol. 98, Iss. 4, pp. S1-S115
Open Access | Times Cited: 962
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
Diabetes Care (2020) Vol. 44, Iss. Supplement_1, pp. S111-S124
Open Access | Times Cited: 890
Diabetes Care (2020) Vol. 44, Iss. Supplement_1, pp. S111-S124
Open Access | Times Cited: 890
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes
Darren K. McGuire, Weichung Shih, Francesco Cosentino, et al.
JAMA Cardiology (2020) Vol. 6, Iss. 2, pp. 148-148
Open Access | Times Cited: 880
Darren K. McGuire, Weichung Shih, Francesco Cosentino, et al.
JAMA Cardiology (2020) Vol. 6, Iss. 2, pp. 148-148
Open Access | Times Cited: 880
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Melanie J. Davies, Louise Færch, Ole K. Jeppesen, et al.
The Lancet (2021) Vol. 397, Iss. 10278, pp. 971-984
Closed Access | Times Cited: 751
Melanie J. Davies, Louise Færch, Ole K. Jeppesen, et al.
The Lancet (2021) Vol. 397, Iss. 10278, pp. 971-984
Closed Access | Times Cited: 751
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Peter Rossing, Maria Luiza Caramori, Juliana C.N. Chan, et al.
Kidney International (2022) Vol. 102, Iss. 5, pp. S1-S127
Open Access | Times Cited: 702
Peter Rossing, Maria Luiza Caramori, Juliana C.N. Chan, et al.
Kidney International (2022) Vol. 102, Iss. 5, pp. S1-S127
Open Access | Times Cited: 702
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, et al.
Diabetes Care (2022) Vol. 46, Iss. Supplement_1, pp. S140-S157
Open Access | Times Cited: 663
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, et al.
Diabetes Care (2022) Vol. 46, Iss. Supplement_1, pp. S140-S157
Open Access | Times Cited: 663
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Julio Rosenstock, Carol Wysham, Juan P. Frías, et al.
The Lancet (2021) Vol. 398, Iss. 10295, pp. 143-155
Closed Access | Times Cited: 655
Julio Rosenstock, Carol Wysham, Juan P. Frías, et al.
The Lancet (2021) Vol. 398, Iss. 10295, pp. 143-155
Closed Access | Times Cited: 655
The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD)
Daniela Maria Tănase, Evelina Maria Gosav, Claudia Florida Costea, et al.
Journal of Diabetes Research (2020) Vol. 2020, pp. 1-16
Open Access | Times Cited: 403
Daniela Maria Tănase, Evelina Maria Gosav, Claudia Florida Costea, et al.
Journal of Diabetes Research (2020) Vol. 2020, pp. 1-16
Open Access | Times Cited: 403
Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice
Hyo Shin Yoon, Chung Hwan Cho, Myeong Sik Yun, et al.
Nature Microbiology (2021) Vol. 6, Iss. 5, pp. 563-573
Closed Access | Times Cited: 388
Hyo Shin Yoon, Chung Hwan Cho, Myeong Sik Yun, et al.
Nature Microbiology (2021) Vol. 6, Iss. 5, pp. 563-573
Closed Access | Times Cited: 388
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Emily Brown, Hiddo J.L. Heerspink, Daniel J. Cuthbertson, et al.
The Lancet (2021) Vol. 398, Iss. 10296, pp. 262-276
Open Access | Times Cited: 383
Emily Brown, Hiddo J.L. Heerspink, Daniel J. Cuthbertson, et al.
The Lancet (2021) Vol. 398, Iss. 10296, pp. 262-276
Open Access | Times Cited: 383
Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs
Angelica Artasensi, Alessandro Pedretti, Giulio Vistoli, et al.
Molecules (2020) Vol. 25, Iss. 8, pp. 1987-1987
Open Access | Times Cited: 376
Angelica Artasensi, Alessandro Pedretti, Giulio Vistoli, et al.
Molecules (2020) Vol. 25, Iss. 8, pp. 1987-1987
Open Access | Times Cited: 376
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
Sandeep R. Das, Brendan M. Everett, Kim K. Birtcher, et al.
Journal of the American College of Cardiology (2020) Vol. 76, Iss. 9, pp. 1117-1145
Open Access | Times Cited: 347
Sandeep R. Das, Brendan M. Everett, Kim K. Birtcher, et al.
Journal of the American College of Cardiology (2020) Vol. 76, Iss. 9, pp. 1117-1145
Open Access | Times Cited: 347
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
Diabetes Care (2021) Vol. 45, Iss. Supplement_1, pp. S125-S143
Closed Access | Times Cited: 337
Diabetes Care (2021) Vol. 45, Iss. Supplement_1, pp. S125-S143
Closed Access | Times Cited: 337
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update
Lawrence Blonde, Guillermo E. Umpierrez, Sarah Reddy, et al.
Endocrine Practice (2022) Vol. 28, Iss. 10, pp. 923-1049
Open Access | Times Cited: 315
Lawrence Blonde, Guillermo E. Umpierrez, Sarah Reddy, et al.
Endocrine Practice (2022) Vol. 28, Iss. 10, pp. 923-1049
Open Access | Times Cited: 315
Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes
Απόστολος Τσάπας, Ioannis Avgerinos, Thomas Karagiannis, et al.
Annals of Internal Medicine (2020) Vol. 173, Iss. 4, pp. 278-286
Closed Access | Times Cited: 261
Απόστολος Τσάπας, Ioannis Avgerinos, Thomas Karagiannis, et al.
Annals of Internal Medicine (2020) Vol. 173, Iss. 4, pp. 278-286
Closed Access | Times Cited: 261
Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment
Ian H. de Boer, Maria Luiza Caramori, Juliana C.N. Chan, et al.
Kidney International (2020) Vol. 98, Iss. 4, pp. 839-848
Open Access | Times Cited: 234
Ian H. de Boer, Maria Luiza Caramori, Juliana C.N. Chan, et al.
Kidney International (2020) Vol. 98, Iss. 4, pp. 839-848
Open Access | Times Cited: 234
Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association
Suzanne V. Arnold, Deepak L. Bhatt, Gregory W. Barsness, et al.
Circulation (2020) Vol. 141, Iss. 19
Open Access | Times Cited: 229
Suzanne V. Arnold, Deepak L. Bhatt, Gregory W. Barsness, et al.
Circulation (2020) Vol. 141, Iss. 19
Open Access | Times Cited: 229
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
Chengxu Ma, Xiaoni Ma, Conghui Guan, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 227
Chengxu Ma, Xiaoni Ma, Conghui Guan, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 227
Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel
Raffaella Buzzetti, Jaakko Tuomilehto, Dı́dac Mauricio, et al.
Diabetes (2020) Vol. 69, Iss. 10, pp. 2037-2047
Open Access | Times Cited: 194
Raffaella Buzzetti, Jaakko Tuomilehto, Dı́dac Mauricio, et al.
Diabetes (2020) Vol. 69, Iss. 10, pp. 2037-2047
Open Access | Times Cited: 194
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial
Takashi Kadowaki, Joakim Isendahl, Usman Khalid, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 3, pp. 193-206
Closed Access | Times Cited: 183
Takashi Kadowaki, Joakim Isendahl, Usman Khalid, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 3, pp. 193-206
Closed Access | Times Cited: 183
Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes
Jae‐Seung Yun, Seung‐Hyun Ko
Metabolism (2021) Vol. 123, pp. 154838-154838
Open Access | Times Cited: 180
Jae‐Seung Yun, Seung‐Hyun Ko
Metabolism (2021) Vol. 123, pp. 154838-154838
Open Access | Times Cited: 180
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials
Brendon L. Neuen, Megumi Oshima, Rajiv Agarwal, et al.
Circulation (2022) Vol. 145, Iss. 19, pp. 1460-1470
Open Access | Times Cited: 176
Brendon L. Neuen, Megumi Oshima, Rajiv Agarwal, et al.
Circulation (2022) Vol. 145, Iss. 19, pp. 1460-1470
Open Access | Times Cited: 176
Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 10th edition
И. И. Дедов, Marina V. Shestakova, Alexander Yu. Mayorov, et al.
Diabetes Mellitus (2022) Vol. 24, Iss. 1S, pp. 1-148
Closed Access | Times Cited: 176
И. И. Дедов, Marina V. Shestakova, Alexander Yu. Mayorov, et al.
Diabetes Mellitus (2022) Vol. 24, Iss. 1S, pp. 1-148
Closed Access | Times Cited: 176
